Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
ASH 2023 – Arcellx still hopes to challenge Carvykti
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
A reprieve for Blenrep?
Against the odds GSK’s Dreamm-7 study yields a positive survival readout.
Gilead ups its bet on Arcellx and BCMA
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
